Activity: Talk and presentation › Professional or public presentation › Professional
Description
1. “Efficacy and Safety of ENZ-124/ Biosimilar Cetuximab versus Innovator Cetuximab in Patients with Recurrent Locoregional or Metastatic Squamous Cell Carcinoma of the Head and Neck: Findings of a Multicentre, Randomised, Double-Blind, Phase III trial in Indian patients”. 2. “A Phase 1b/2 Study of Nanatinostat (Nstat) Plus Valganciclovir (VGCV) in EBV+ Solid Tumors and with Pembrolizumab (PEM) in Recurrent/Metastatic Nasopharyngeal Carcinoma (R/M NPC)”.